The Role of Circulating Tumor DNA in Uveal Melanoma
Author Information
Author(s): Zameer Mohammed Zeeshan, Jou Eric, Middleton Mark
Primary Institution: University of Oxford
Hypothesis
Can circulating tumor DNA (ctDNA) improve early detection and monitoring of uveal melanoma?
Conclusion
Circulating tumor DNA has the potential to enhance early detection and monitoring of uveal melanoma, which could lead to better patient outcomes.
Supporting Evidence
- ctDNA levels correlated with disease burden in metastatic uveal melanoma patients.
- Early detection of ctDNA may precede clinical diagnosis of metastasis by 2-10 months.
- ctDNA can help predict treatment response and monitor disease progression.
Takeaway
This study looks at how a special type of DNA found in the blood can help doctors find and treat a serious eye cancer called uveal melanoma earlier.
Methodology
The review discusses existing evidence and potential clinical applications of ctDNA in uveal melanoma, including its use in diagnosis, monitoring, and treatment response.
Potential Biases
Potential biases may arise from the reliance on existing studies and the variability in ctDNA detection methods.
Limitations
Current use of ctDNA in uveal melanoma is largely limited to research settings, and further validation is needed for clinical application.
Participant Demographics
The study references a retrospective analysis of 8033 eyes with uveal melanoma.
Statistical Information
P-Value
p<0.001
Confidence Interval
95% CI 53-70
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website